Bli medlem
Bli medlem

Du är här


Immunovia AB: Immunovia Year-end report 2015

"In 2015 Immunovia took important steps toward commercialisation of
the world's first blood-based test for cancer diagnosis, IMMray™
PanCan -d. We were able to prove, with 96% accuracy, that our test
can diagnose the early stages of pancreatic cancer. In the second
half of the year we signed a comprehensive agreement with Knight
Cancer Institute at Oregon Health & Science University, USA, which
during the year received a donation of USD 1 billion to achieve
radical changes in cancer care globally through a focus on early
diagnosis. Cooperation with Knight Cancer Institute will be decisive
for the forthcoming market launch of our test, and furthermore, it
will through joint research projects increase our pipeline of tests
for other forms of cancer. At the start of 2016 we announced two
further collaborations, one with the University of Liverpool, UK, and
one with Mount Sinai Cancer Center, USA, which together with Knight
Cancer Institute will be involved in a prospective validation of
IMMray™ PanCan -d. This study will start in the second half of 2016
and run for three years, in parallel with the sales start in 2017 to
out-of-pocket customers. Revenue streams are expected to start in

In 2016 we will conclude quality assurance at our laboratory in Lund,
Sweden, and apply for ISO accreditation. Once this is approved we
will be able to receive tests from throughout Europe for early
diagnosis of pancreas cancer and we are already in discussions with
several prospective customers, i.e. cancer centres and laboratories.

In December 2015 Immunovia was listed on Nasdaq First North in
Stockholm and in connection with this listing raised SEK 60 million
through a new share issue. Together with the SEK 40 million the
company received in the form of a grant from the EU in May, the
company now has the financial stability for the market launch of
IMMray™ PanCan -d."

Mats Grahn, CEO Immunovia AB

|Key indicators|

|SEK 000 unless |1 July-31|1 July-31|Full year 2015|Full year 2014|
|otherwise stated |Dec. 2015|Dec. 2014| | |
|Net sales | 147| 256| 205| 359|
|Operating earnings | -3 588| -6 124| -7 424| -8 959|
|Earnings before tax| -3 577| -6 023| -7 384| -8 859|
|Net earnings | -3 577| -6 023| -7 384| -8 859|
|Earnings per share | -0,30| -0,55| -0,65| -0,99|
|before dilution | | | | |
|(SEK/share) | | | | |
|Earnings per share | -0,29| -0,52| -0,62| -0,93|
|after dilution | | | | |
|(SEK/share) | | | | |


Immunovia is focused on fundamentally transforming the diagnosis of
complex forms of cancer and autoimmune diseases. The antibody-based
platform, IMMray™, is the result of 15 years of research at CREATE
Health - the Center for Translational Cancer Research at Lund
University, Sweden. IMMray™ is a technology platform for the
development of diagnostic tests, and the company's primary test
IMMray™ PanCan-d is the first test in the world for early diagnosis
of pancreatic cancer.

·It is planned to launch IMMray™ PanCan-d on the American and European
markets with sales start in 2017 to out-of-pocket customers, with
revenues expected to begin in 2018. In coming years Immunovia will
address a market that in total is worth around SEK 30 billion.

·Immunovia sees great potential in the development of tests for other
unsolved problems in cancer and autoimmune diseases via its IMMray™
platform. The next focus area will be tests within SLE.

* No changes compared with the Prospectus dated 30 October 2015 that
was concerned with the new issue of shares in connection with the
listing on the First North exchange.

For further information, please contact:
Mats Grahn, CEO, Immunovia AB
Phone: +46 (0) 70-532 02 30

See also the company's website:


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.